Skip to main content
Caplight Logo









Trishula Therapeutics

Trishula Therapeutics

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://trishulatx.com

Last Round

Spinoff

Aug 26, 2020

Company Overview

Trishula Therapeutics is a biotechnology company that develops cancer immunotherapies, specifically focusing on its first-in-class anti-CD39 antibody, TTX-030.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologycancer immunotherapymonoclonal antibodysolid tumorsclinical trialsdrug developmentoncologybiotechanti-CD39tumor microenvironmentdrug discoveryclinical-stage biotechbiopharmatherapeutic pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Trishula Therapeutics Comparables

Compare Trishula Therapeutics with similar companies based on industry and business-model similarity.

Trishula Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tizona Therapeutics
91%
Arcus Biosciences
83%
Coherus BioSciences Inc
81%

Trishula Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SpinoffAug 26, 2020

Trishula Therapeutics Investors

Notable investors and investment history

Trishula Therapeutics investors
InvestorRounds
InterWest PartnersSpinoff
Lightstone VenturesSpinoff
MPM BioImpactSpinoff
AbbVie VenturesSpinoff
AbingworthSpinoff
Canaan PartnersSpinoff

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 26, 2020

    Raised a spinoff round with investors including Canaan Partners and AbbVie Ventures.

Trishula Therapeutics Filings

Explore SEC and related filing metadata, where available.

Trishula Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Trishula Therapeutics's valuation, stock price, and market status.

Is Trishula Therapeutics a public or private company?

Trishula Therapeutics is a private company.

What is the current stock price of Trishula Therapeutics?

Trishula Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Trishula Therapeutics worth (valuation)?

Valuation information for Trishula Therapeutics is not publicly available.

Can I buy Trishula Therapeutics stock?

Trishula Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Trishula Therapeutics's last funding round?

Trishula Therapeutics's most recent funding round was Spinoff on August 26, 2020.

Who are the main investors in Trishula Therapeutics?

Key investors in Trishula Therapeutics include InterWest Partners, Lightstone Ventures, MPM BioImpact, AbbVie Ventures, Abingworth.

Will Trishula Therapeutics IPO soon?

No public IPO plans have been announced for Trishula Therapeutics.

How can I track Trishula Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Trishula Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range6
Year Founded2020
Last FundingAug 26, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?